How iQOS Drives Philip Morris Growth and Innovation in Q1 2026

Answer outline

• The core reason: headroom created by (a) strong underlying H1 trajectory and (b) confidence that H2 will stay “dynamic” rather than slow
• How the guidance can stay steady even with higher-than-expected Q1/Q2: management cited offsetting items and timing effects (not a single “one factor”)
  • Smoke-free: IMS vs shipment timing was expected to be unfavorable in H1 and favorable later (i.e., a reshaping of revenue growth timing)
  • Management also highlighted H2 dynamic growth and an operating income acceleration target (supporting the “no change” stance on underlying profitability trajectory)
  • U.S. investment/phasing: higher U.S. growth investment in H2 was framed as a deliberate cost/margin timing effect that counterbalances operational upside
• Quantifying the split you asked for: what portion was U.S. investment/phasing vs smoke-free IMS/shipment phasing?
  • What can be answered from the excerpts (with intellectual honesty)
  • Therefore, the best-supported qualitative answer to your split question
  • A reasonable numerical estimate cannot be produced from these excerpts
• Putting it together: the logic chain PMI used to keep guidance intact

Answer outline

• What management said happened to pricing right after the Japan excise change
• How pricing “pass-on” is expected to evolve after the worst disruption
• Competitive implications: promotions and how pricing pressure may change
• Why management expects a more favorable pricing environment after near-term disruption
• Tie to what happened operationally to pricing/timing vs. volume

Answer outline

• Why full-year underlying growth guidance is unchanged despite strong H1
  • Management says the guidance is maintained because H1 performance fits the overall trajectory, and H2 is expected to be dynamic rather than slowing
  • The company notes H1’s margin picture includes higher investment and expects higher SG&A in H2, but not a deterioration that forces guidance changes
  • Management ties the unchanged guidance to a balance between improved smoke-free growth drivers and mix/phasing effects (including IQOS volume mechanics)
• The plan for higher U.S. investments in H2
  • PM’s core rationale: use H2 investment to accelerate ZYN brand equity and portfolio expansion
  • Management describes the U.S. investment goal as optimizing growth and the bottom line (not simply spending more)
  • What it says about the nature of spending: commercial activity and marketing—especially around ZYN—and some evidence of reduced promotions in Q2
• Will H2 promotional spending behind ZYN rise? (and how PM addresses the question)
  • PM signals more commercial/marketing activity in H2, but avoids committing to “a big step-up” in promotional spend details
  • It provides directional context on promotions: Q2 was reduced; H2 will include increased commercial activity and portfolio expansion
  • PM’s positioning effort suggests promotional intensity is being used to strengthen premium leadership rather than being framed as ad-hoc discounting
• Practical interpretation: why unchanged guidance is consistent with higher H2 U.S. investments

Answer outline

• Margin expectations for Q1 2026 (what management highlighted)
  • Smoke-free (international) gross margin
  • IQOS is the primary margin driver within smoke-free
  • Other smoke-free initiatives (e.g., VEEV / IQOS by bonds)
• Pricing strategies expected/being used in Q1 2026
  • International smoke-free: selective price increases
  • How they think about price vs. volume / competitiveness in the U.S. nicotine pouches (ZYN)
• Key relationship between pricing and margin in Q1 2026 (what management explicitly connected)
• Conclusion (direct answer)

Answer outline

• Philip Morris: expected Q1 2026 margins & pricing strategy (from the provided Q1 2026 earnings transcript)
• Margins: where they’re expected to be strong (and why)
  • Smoke-free / International: gross margins already very high, supported by pricing + portfolio mix
  • IQOS profitability trajectory: margin expansion supported by pricing and productivity/cost actions
• Pricing strategies expected in Q1 2026 (what management signals it will do)
  • Smoke-free international pricing: moderate price increases, with IQOS as the main engine
  • U.S. nicotine pouches (ZYN): premium strategy with attention to the “price gap” and competition
• What the excerpts imply about “expected” Q1 2026 results (without over-claiming numbers)
  • What can be stated from the transcript
  • What cannot be concluded from the excerpts
• Bottom line (Q1 2026 expectations, as supported by the excerpts)

Answer outline

• Key Points and Context
• Business Implications
• Conclusion

Answer outline

• What management said about THERABREATH (substantive points)
  • THERABREATH is performing strongly vs. expectations (“early innings”)
  • Share gains and category position were called out directly
  • Volume/consumption momentum
  • THERABREATH is contributing to net sales, and may have been a bit stronger than expected
• Interpretation of the phrase itself (“Sorry, THERABREATH, you’re right?”)
• Bottom line

Answer outline

• China EV-driven growth: penetration, share gains, and expected outperformance
• China margins: near-term headwinds vs structural improvement from higher-margin new content
• Bottom line: what management said about China specifically vs overall Automotive margins

Answer outline

• Industrial Solutions was the main engine of growth
• Advanced Solutions was mixed: medical and semiconductor helped, but other areas declined
• Product/application mix and “battery manufacturing + healthcare” demand themes
• Geographic contributors (supporting evidence)
• One mechanical factor: foreign currency helped somewhat

Answer outline

• Demand was strong and broad-based in Q1 2026, with wearables a meaningful growth contributor
• 2) “Advanced wearables” demand was particularly strong; both low and high tiers showed strength
• The demand driver appears to be unit-volume growth and share gains (not just pricing)
• Health-focused engagement themes: reproductive-health capability and continued consumer wellness awareness
• Ecosystem/connectedness appears to be supporting continued adoption and engagement

Answer outline

• Overall Handgun Unit Shipments:
  • Handgun unit shipments into the sporting goods channel increased by 28% year-over-year in Q3 2026.
  • New products represented 44% of handgun shipments during the quarter, evidencing strong consumer adoption of recently introduced SKUs, including the compact and full-size polymer pistols [[cite:7656314702811]].
• SKU Tier Demand Insights:
  • The company highlighted a favorable shift in product mix toward higher price models, which includes compact and full-size polymer pistols that are positioned above the subcompact tier.
  • The polymer pistol line, extending beyond subcompact models into compact and full-size SKUs, has started to gain “a lot of profitable share.” This expansion into larger frames is at the higher end of the pricing hierarchy, contributing positively to average selling prices (ASPs) and unit demand momentum [[cite:7656314702862]].
  • While no explicit unit sales breakdown by individual SKU tiers was disclosed, the following points allow an approximate assessment:
• Average Selling Price (ASP) Impact:
  • Handgun ASPs were up approximately 5.2% year-over-year to over $419, driven by the shift towards higher-priced models included in the compact and full-size polymer pistol range [[cite:7656314702826]].
  • The ASP increase alongside volume growth confirms solid unit demand in these SKU tiers, which cater to consumers willing to pay premiums for enhanced features and larger frame sizes.
• New compact and full-size polymer pistol models making up a significant and growing portion of the 44% new product shipments within handguns, contributing heavily to the 28% overall unit shipment increase in the handgun category.
• These SKU tiers are driving a favorable product mix shift towards higher price points, as reflected in improved ASPs and profitable market share gains.